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Survival rates among children with leukaemia in low-income countries are lower than those in high-income countries. This has been
attributed in part to higher treatment-related mortality (TRM). We examined the demographics, treatment, and outcomes of
paediatric patients in El Salvador with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML) to determine the
incidence, causes, and risk factors for TRM. Two trained data managers collected data prospectively; no patients were excluded.
Biological, socioeconomic and nutritional predictors were examined. A total of 469 patients with ALL and 78 patients with AML were
included. The 2-year cumulative incidence of TRM was significantly higher among children with AML (35.4±6.4%) than those with
ALL (12.5±1.7%; Po0.0001). However, the proportion of deaths attributable to the toxicity of treatment did not differ significantly
between AML (25/47, 53.2%) and ALL (55/107, 51.4%; P¼0.98). Among children with ALL, low monthly income (P¼0.04) and low
parental education (P¼0.02) significantly increased the risk of TRM. Among children with AML, biological, socioeconomic, and
nutritional variables were not associated with TRM. In this low-income country, toxic death significantly contributes to mortality in
both ALL and AML. A better understanding of the effect of socioeconomic status on TRM may suggest specific strategies for patients
with ALL.
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The past four decades have seen steady improvements in treatment
outcomes for children with leukaemia. In high-income countries
(HICs), overall cure rates of approximately 80% have been
achieved in acute lymphoblastic leukaemia (ALL) (Pui and Evans,
2006). Recent trials in children with acute myeloid leukaemia
(AML) also have shown improved outcomes and have resulted
in event-free survival (EFS) of approximately 50% (Stevens
et al, 1998; Ravindranath et al, 2005; Creutzig et al, 2006). These
advances have been attributed to more efficacious use of
antileukaemic agents, intensification of treatment when appro-
priate, identification of prognostic factors for risk stratification,
and improvements in supportive care (Ravindranath et al, 2005;
Pui and Evans, 2006).
Unfortunately, these advances in survival have not fully
translated into low-income countries (LICs) where EFS is
significantly lower than in HICs. Potential reasons for different
survival rates include a higher rate of relapse, more abandonment
of treatment, and higher rates of treatment-related mortality
(TRM) in LICs. Improvements in outcome may be achieved by
improving disease control, reducing abandonment, and reducing
TRM. The latter becomes particularly important in LICs where
TRM is an important contributor to poor outcomes.
The primary objectives of this study were to determine the
incidence and causes of TRM among children with ALL and AML
in El Salvador. The secondary objectives were to determine
predictors of TRM in the same population and to describe TRM in
El Salvador relative to published results in HICs and other LICs.
MATERIALS AND METHODS
Data source
Data were obtained from the Pediatric Oncology Networked
Database (POND) (http://www.pond4kids.org). POND is an online
database for paediatric cancer patient information designed to
permit users at multiple locations to store and analyse data that
include patient demographics, diagnoses, treatments, and out-
comes in a secure environment with stringent control of access and
privacy. Although the primary purpose of data collection is to
monitor patient outcomes and implement quality improvement
initiatives, data also can be extracted without personal identifiers
for research. At the paediatric cancer centre in El Salvador, two
data managers recorded information about patients and their
outcomes in real time through chart abstraction. In El Salvador, as
in 30 other countries, information about paediatric oncology
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spatients is collected routinely, and includes data on patient
demographics, nutrition, socioeconomic status, diagnosis, treat-
ment, complications, and outcomes. A recent audit of POND data
quality conducted in Honduras, where a similar data management
program is in place, showed that accuracy for basic data fields was
99% (Ayoub et al, 2007).
Study population
The patient sample consisted of children with ALL and AML
treated at the Benjamin Bloom National Children’s Hospital (San
Salvador, El Salvador). This is the sole treatment centre for
children with cancer in the country, in which approximately 200
new patients are treated a year. We included those aged 0–16 years
at diagnosis who had de novo ALL or AML and were diagnosed
between 1 January 2000 and 1 July 2007. Patients with acute
promyelocytic and mature B-cell leukaemia were excluded.
Patients with ALL were treated according to the El Salvador-
Guatemala-Honduras II protocol, which was based on the St Jude
Total XIII (Pui et al, 2004b) and Total XV (Pui et al, 2004a)
protocols. Significant modifications included the use of only two
risk groups (lower and higher, Table 1), the omission of etoposide,
and the administration of high-dose methotrexate as a 3-h infusion
at a dose of 2gm
 2 for lower risk and 3gm
 2 for higher risk
patients.
Between January 2000 and December 2006, patients with AML
were treated according to the AHOPCA-AML 1999 protocol, which
was based on BFM-AML93 (Creutzig et al, 2001). Significant
modifications included the treatment of all children as low risk
(without stem cell transplantation, which is unavailable in the
region), reduction of daunorubicin by 66%, omission of etoposide
during induction and intensification, omission of cyclophospha-
mide during consolidation, use of high-dose cytarabine and
mitoxantrone only in patients without response after induction
plus consolidation, and reduction of maintenance therapy to 12
months. After January 2007, patients with AML were treated with
the AHOPCA-AML 2007 protocol, based on NOPHO-AML 93 (Lie
et al, 2003). Significant modifications included induction therapy
as per AHOPCA-AML 1999 (BFM-AML93), but with the addition
of etoposide.
The oncology unit at the Benjamin Bloom Hospital has 30 in-
patient beds: two single rooms and four other rooms with capacity
for seven patients in each room. These rooms do not have air
filters. Infection control methods include surveillance for nosoco-
mial infections and quality control programs targeting hand
washing and central line care. All children with febrile neutropenia
are admitted and started on broad-spectrum antibiotics. Vanco-
mycin and ceftazidime are used in patients with hypotension or
other signs of sepsis. Antifungal coverage is initiated in the case of
persistent fever. Overall 80% of blood product requests are met
expeditiously; the remaining are met within 24h.
Abandonment of therapy is a significant treatment challenge in
LICs, and efforts to prevent abandonment are an important
component of care. In El Salvador, social workers contact families
who abandon therapy by telephone. When this is not possible,
local health providers visit the patient’s home and community to
encourage the resumption of treatment. As our study focused on
TRM rather than all causes of treatment failure, patients who
abandoned treatment were censored in the analysis because they
were no longer at risk for TRM. In studies of other clinical
outcomes, abandonment is generally treated as an event, with a
corresponding decrement in the EFS when a patient abandons
treatment.
Outcome measures
Treatment-related mortality was defined as death unrelated to
refractory or progressive disease occurring before first remission
was achieved, or any death in complete remission. Death in
complete remission was defined as any death occurring 42 days or
later after diagnosis in patients who achieved remission. These
definitions are consistent with those used by others (Christensen
et al, 2005; Slats et al, 2005) to facilitate future comparisons across
studies.
All cases of TRM were also sub-divided by specific cause of
death into four categories as follows: infection, bleeding, organ
failure, and metabolic (predominantly tumour lysis syndrome).
Non-TRM causes of death (i.e., death from progressive disease)
also were recorded.
Potential predictors
Several variables were examined as potential predictors of TRM.
These were categorized as biological, socioeconomic, and nutri-
tional. Biological variables included age, sex, initial cell counts,
DNA index (ALL), cell lineage (B precursor vs T-cell immunophe-
notype for ALL), risk stratification (higher vs standard for ALL),
the and French-American-British classification (M5 vs others for
AML; Riley et al, 1999). Socioeconomic variables included monthly
income, cost and time to travel to clinic, number of family
Table 1 Patient demographic characteristics by diagnosis
Characteristic ALL AML
Age in years, median (range) 5.2 (0.0, 15.1) 5.5 (0.2, 15.7)
Male, N (%) 263 (56) 40 (51)
Initial WBC (10
9l
 1) median (IQR) 11.5 (4.5, 36.3) 15.8 (6.7, 56.6)
Initial haemoglobin (gl
 1), median (IQR) 69 (51, 90) 77 (50, 97)
Immunophenotype, no (%)
B lineage 421 (92)
T lineage 35 (8)
FAB classification, N (%)
M0 7 (9)
M1 18 (24)
M2 26 (34)
M4 8 (11)
M5 6 (8)
M6 2 (3)
M7 7 (9)
Risk group, N (%)
Higher risk 194 (44)
Standard risk
a 250 (56)
Parental education, N (%)
Illiterate 17 (4) 3 (4)
Primary 290 (63) 51 (67)
Secondary 107 (23) 18 (24)
Advanced 41 (9) 3 (4)
Unknown 4 (1) 1 (1)
Hours to travel to clinic, median (IQR) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0)
Monthly household income (dollars),
median (IQR)
150 (100, 250) 150 (57, 228)
Body mass index percentile, median (IQR) 43.2 (11.1, 81.3) 41.2 (10.7, 77.8)
Triceps skin-fold thickness percentile,
median (IQR)
17.5 (2.5, 62.5) 37.5 (17.5, 62.5)
Mid-upper arm circumference percentile,
median (IQR)
17.5 (2.5, 37.5) 17.5 (2.5, 37.5)
Abbreviations: ALL¼acute lymphoblastic leukaemia; AML¼acute myeloid leukae-
mia; FAB¼French-American-British; IQR¼interquartile range; N, number; WBC,
white blood cell count; .
aStandard risk was defined as DNA index X1.16, WBC
o50 10
9/l, age 412 months and o10 years, without any of the following: (1)
T-cell lineage, (2) CNS leukaemia at diagnosis, (3) testicular leukaemia or (4) bone
marrow M3 on day 15 or M2-M3 on day 36.
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smembers (all continuous variables), parental education (secondary
level or greater vs primary level or less), and the presence of a
household telephone. If educational achievement differed among
caregivers within a family, the maximal achievement was
considered for the analysis. Nutritional variables included body
mass index percentile, triceps skin-fold thickness percentile, and
mid-upper arm circumference percentile. Body mass index
percentile was calculated relative to the 2000 growth charts
published by the Centers for Disease Control and Prevention
(Ogden et al, 2002). Triceps skin-fold thickness provides a
measure of fat mass, whereas the mid-upper arm circumference
is a measure of lean mass (Sala et al, 2004). These two variables
were chosen as they have been previously suggested to be ‘gold
standard’ measures of nutritional status (Sala et al, 2008).
Statistical methods
The cumulative incidence of TRM was calculated using the
Kaplan–Meier method. For this analysis, relapse and abandon-
ment of therapy were censored as competing events with TRM,
which was compared between ALL and AML using the log rank
test. The proportion of mortality attributable to treatment in
general and to specific causes of death was compared between ALL
and AML using the w
2 test or Fisher’s exact test as appropriate.
Univariate and multi-variable Cox proportional hazards models
were used to explore potential predictors of TRM. Variables with a
P-value o0.1 on univariate analysis were examined in the multiple
regression models. Statistical analyses were performed using SAS-
PC software (version 8.0; SAS Institute, Cary, NC, USA) or the
Statistical Package for Social Sciences for Windows (version 10.1;
SPSS, Chicago, IL, USA). Statistical significance was defined as
Po0.05. The study was approved by the research ethics
committees at The Hospital for Sick Children and the Benjamin
Bloom National Children’s Hospital.
RESULTS
In the time frame of interest, 547 patients were treated on the
protocols, and all were included in the analysis; 469 had ALL and
78 had AML. Demographic data are shown in Table 1. Two- and 5-
year EFS rates were 67.7±2.4 and 47.3±3.5% for ALL and
28.3±5.6 and 23.6±5.6% for AML (Po0.0001). Two- and 5-year
overall survival rates were 79.8±2.1 and 61.1±3.7% for ALL and
34.9±6.3 and 26.8±6.3% for AML (Po0.0001). The 2-year
cumulative incidence of TRM was 12.5±1.7% for ALL and
35.1±6.4% for AML (Po0.0001).
There were 107 deaths in the ALL group and 47 in the AML
group (Table 2). The proportion of these deaths attributable to
treatment was similar to children with ALL (51.4%) and AML
(53.2%, P¼0.98). Similarly, there was no difference in the
proportion attributable to the four most common causes of TRM
(infection, bleeding, organ failure, and metabolic) by diagnosis.
Table 3 shows the univariate analyses examining predictors of
TRM. Among patients with ALL, lower monthly income (hazard
ratio (HR) per $100¼0.81; 95% CI: 0.66, 0.99; P¼0.04, Figure 1)
and lower parental education (HR¼0.46, 95% CI: 0.23, 0.89;
P¼0.02, Figure 2) significantly increased the risk of TRM. For
children whose maximum parental educational achievement was at
least secondary school level, the 2-year cumulative incidence of
Table 2 Percentage of mortality attributable to treatment and specific
causes of death stratified by diagnosis
ALL AML P-value
Total number of deaths 107 47
Morality attributable to
Treatment, N (%) 55 (51.4) 25 (53.2) 0.98
Disease, N (%) 52 (48.6) 22 (46.8)
Specific causes of TRM
Infection 38 (70.4) 14 (60.9) 0.4
Bleed 10 (18.5) 7 (30.4)
Organ failure 3 (5.6) 2 (8.7)
Metabolic 3 (5.6) 0
Abbreviations: ALL¼acute lymphoblastic leukaemia; AML¼acute myeloid leukae-
mia; TRM¼treatment-related mortality.
Table 3 Univariate analysis of biological, socioeconomic, and nutritional variables as predictors for TRM stratified by diagnosis
ALL AML
HR (95% CI) P-value HR (95% CI) P-value
Biological variables
Age (years) 0.93 (0.85, 1.02) 0.13 0.99 (0.89, 1.11) 0.90
DNA index 0.57 (0.20, 1.63) 0.29
B-precursor immunophenotype 0.53 (0.26, 1.09) 0.08
High-risk group 0.86 (0.50, 1.49) 0.60
FAB class (M5 vs other) 1.95 (0.57, 6.66) 0.29
Initial WBC (per 10 10
9/l) 1.00 (1.00, 1.00) 0.05 1.00 (1.00, 1.00) 0.31
Initial haemoglobin (gl
 1) 0.98 (0.91, 1.07) 0.70 1.01 (0.87, 1.17) 0.88
Socioeconomic variables
Hours to clinic 0.97 (0.84, 1.11) 0.61 1.01 (0.73, 1.39) 0.96
Cost to travel to clinic 1.02 (0.93, 1.11) 0.72 1.08 (0.79, 1.50) 0.62
Income (per $100) 0.81 (0.66, 0.99) 0.04 1.04 (0.89, 1.22) 0.61
Presence of telephone 0.75 (0.41, 1.36) 0.34 1.04 (0.41, 2.68) 0.93
Number of family members 0.94 (0.80, 1.09) 0.39 0.98 (0.81, 1.18) 0.82
Parental education category 0.46 (0.23, 0.89) 0.02 0.94 (0.36, 2.42) 0.89
Nutritional variables
Body mass index percentile 1.00 (0.99, 1.02) 0.42 1.00 (0.99, 1.02) 0.87
Triceps skin-fold thickness percentile 1.00 (0.98, 1.02) 0.86 1.02 (0.98, 1.06) 0.29
Mid-upper arm circumference percentile 1.01 (0.99, 1.03) 0.38 1.03 (1.00, 1.06) 0.06
Abbreviations: ALL¼acute lymphoblastic leukaemia; AML¼acute myeloid leukaemia; BMI¼body mass index; CI¼confidence interval; HR¼hazard ratio; TRM¼treatment-
related mortality; WBC¼white blood cell count.
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sTRM was 7.1±2.3%. For children whose parental maximal
educational achievement was less than the secondary school level
(i.e., primary school or illiterate), the 2-year cumulative incidence
of TRM was 15.0±2.3% (P¼0.02). Both higher initial white blood
cell count (HR per 10 10
9 cells/l¼1.00, 95% CI: 1.00, 1.00;
P¼0.05) and non-B precursor immunophenotype (HR¼0.53,
95% CI: 0.26, 1.09; P¼0.08) were non-significantly associated with
increased risk of TRM.
As monthly income and parental education were highly
correlated (Spearman’s correlation coefficient¼0.46, Po0.0001),
they could not be examined in the same multiple regression model.
When each of monthly income and parental education were placed
in multivariable models with initial white blood cell count and
B-precursor immmunophenotype, both remained independently
predictive of TRM (monthly income adjusted HR per $100¼0.81,
95% CI: 0.66, 0.99; P¼0.04; higher parental education adjusted
HR¼0.47, 95% CI: 0.24, 0.91; P¼0.03). In both multivariable
models, neither initial white blood cell count nor immunopheno-
type remained independently predictive of TRM.
Among patients with AML, neither biological, socioeconomic,
nor nutritional measures were associated with TRM (Table 3).
Table 4 illustrates our estimates of TRM relative to those shown
in HICs and other LICs.
DISCUSSION
Despite significant reductions in treatment intensity, more than
10% of children with ALL and about one-third of children with
AML die of TRM in El Salvador, which constitutes about half of the
deaths in each disease. Finally, lower socioeconomic status is
associated with higher TRM in ALL but not in AML.
Our estimates are consistent with those reported in other LICs
(Table 4). However, our report is the first to compare the relative
contribution of TRM with treatment failure for children with ALL
and AML in an LIC. In HICs, TRM accounts for more treatment
failure in children with AML than ALL (Christensen et al, 2005;
Ravindranath et al, 2005; Slats et al, 2005; Creutzig et al, 2006; Pui
and Evans, 2006). Our finding suggests that in LICs, efforts to
reduce TRM are as important for children with ALL as for those
with AML.
Our study is also unique, as we were able to examine
socioeconomic and nutritional variables and their impact on
TRM in addition to the traditional biological and clinical factors.
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Figure 1 Cumulative incidence of treatment-related mortality in ALL
stratified by monthly family income 4$150 or p$150.
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Figure 2 Cumulative incidence of treatment-related mortality in ALL
stratified by parental education.
Table 4 Various rates of TRM in ALL and AML in both HICs and LICs
Reference Protocol HIC vs LIC Country TRM (%)
ALL
Christensen et al (2005) NOPHO ALL92 HIC Nordic 3.0
Slats et al (2005) DCOG ALL-6, 7 and 8 HIC The Netherlands 2.1
Rubnitz et al (2004) Total Therapy XI-XIV HIC United States 2.9
Li et al (2003) HKALL 93 HIC Hong Kong 2.8
Wheeler et al (1996) MRCUKALLX HIC United Kingdom 5.6
Gupta S et al (current) St. Jude’s Modified LIC El Salvador 12.5
Howard et al (2004) Total XI, Total XIII LIC Brazil 14.9
Metzger et al (2003) St. Jude’s Modified LIC Honduras 20.8
Laosombat et al (2002) Modified CCSG LIC Thailand 11.5
Advani et al (1999) MCP841 LIC India 16.0
Aziz et al (1997) Modified BFM LIC Pakistan 14.3
AML
Creutzig et al (2006) AML-BFM 98 HIC Various 7.2
Ravindranath et al (2005) POG 8821 HIC Various 14.4
Slats et al (2005) DCOG AML-82, 87 and 92/94 HIC Netherlands 16.6
Creutzig et al (2004) AML-BFM 93 HIC Various 9.7
Rubnitz et al (2004) AML-83, 87, 91, 97 HIC United States 7.6
Riley et al (1999) UKMRC AML10 HIC Various 13.8
Gupta S et al (current) Modified BFM93 LIC El Salvador 33.1
Dluzniewska et al (2005) PPLLSG 98 LIC Poland 18.0
Abbreviations: ALL¼acute lymphoblastic leukaemia; AML¼acute myeloid leukaemia; HIC¼high-income countries; LIC¼low-income country; TRM¼treatment-related
mortality.
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HICs (Wheeler et al, 1996; Riley et al, 1999; Creutzig et al, 2004;
Rubnitz et al, 2004; Christensen et al, 2005; Slats et al, 2005),
very few have looked at similar risk factors in LICs (Advani et al,
1999). Among patients with ALL in HICs, studies have identified
gender, age, high white blood cell count, high-risk ALL, T-ALL,
and Down’s syndrome as TRM risk factors, although these have
not been consistent (Wheeler et al, 1996; Rubnitz et al, 2004;
Christensen et al, 2005; Slats et al, 2005). Conversely, Advani et al
(1999) found that in the LIC of India, low haemoglobin,
lymphadenopathy, and malnutrition were all associated with
increased risk of TRM in ALL. They theorised that underlying
population biological features as well as more advanced stage at
presentation may change the underlying relationships between
clinical parameters and TRM.
For children with ALL in El Salvador, in contrast to the above-
cited reports in both HICs and LICs, we found that biological
factors were not associated with TRM in multiple regression
models, and that only poorer socioeconomic status independently
predicted TRM. More specifically, only lower household income
and lower parental education were associated with higher risk of
TRM in ALL. These socioeconomic variables may be proxies for
several factors, some of which have been proposed to explain the
outcome gap between HICs and LICs (Howard and Wilimas, 2005).
These factors include more advanced stage due to delayed
presentation and diagnosis, underlying malnutrition, abandon-
ment of treatment (censored in this analysis), delayed recognition
of treatment-related complications, or decreased ability to seek
prompt medical attention. Initial white blood cell count, measures
of malnutrition, and the time and cost of travelling to clinic were
not significantly associated with TRM in our study, therefore
suggesting that delayed presentation, malnutrition, and distance
from the treating facility were not important contributors to TRM
in El Salvador. Further research is therefore required to better
understand the pathways through which socioeconomic status
exerts its negative effect on outcome in ALL.
These findings have implications for future interventions aimed
at reducing TRM. Patients of lower socioeconomic status may
benefit from more aggressive supportive care in hospital. However,
the significant role of socioeconomic status in predicting TRM
suggests that further improvements to supportive care may not be
as effective in patients with childhood leukaemia as interventions
targeting pre-hospital care. Educational efforts aimed at helping
parents recognise treatment-related complications may have the
greatest impact.
In AML within HICs, female gender, age, high white blood
cell count, low performance status at treatment initiation, M5
histology, and the central nervous system status have all been
identified as increasing the risk for TRM, although again
these findings have varied significantly from study to study (Riley
et al, 1999; Creutzig et al, 2004; Rubnitz et al, 2004; Slats et al,
2005). A recent study examining children with AML enrolled on a
Children’s Cancer Group clinical trial found that age 416 years,
non-white ethnicity, and underweight status were all significantly
associated with infection-related mortality (Sung et al, 2007). We
did not find that malnutrition influenced TRM in our study. The
difference in the effect of malnutrition between the Children’s
Cancer Group trial and our data may be related to the differences
in treatment, underlying differences in study populations, or lack
of power in our study.
Strengths of this study include the population-based nature of
its data source; there is only one paediatric oncology treatment
centre in El Salvador whose patients are all captured by POND.
Another is our ability to examine numerous socioeconomic and
nutritional variables in addition to clinical and biological factors.
Finally, active community follow-up in cases of abandonment of
treatment ensures that cases of mortality are not missed or
misclassified. Our report is limited by the relatively small number
of children with AML available, thus limiting power in this cohort.
In addition, the POND database does not capture those patients
who died before reaching the central treatment centre.
Treatment-related mortality was higher in AML than in ALL in
this LIC; however, the proportion of mortality attributable to
treatment was similar. Socioeconomic factors predicted the risk of
TRM within ALL. Future work should include efforts to under-
stand the various pathways through which socioeconomic status
may affect TRM and to design and evaluate interventions to reduce
TRM in ALL. Multi-centre studies across Central America are
needed to better study TRM in AML.
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